SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maulcoin

Maulcoin is surging as a community-driven movement that emphasizes organic growth and a 'diamond hand' holding strategy over traditional pump-and-dump tactics. Investors are actively discussing the project's potential to reach significant market milestones, frequently highlighting their dedication to the 'Mauler' brand as they await broader chart integration.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir shares are seeing high volatility as investors weigh a direct presidential endorsement against bearish pressure from notable short-sellers who argue the company's valuation is detached from fundamentals and threatened by emerging AI competitors. The community remains deeply divided, with some betting on a massive short squeeze and institutional accumulation while others warn that the stock is caught in a wider software sector correction.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing intense market activity and social media buzz driven by speculation around high-profile partnerships, upcoming festival events, and its role in a decentralized music-event ecosystem. The community is sharply divided, with enthusiasts highlighting aggressive accumulation and technical breakout potential, while critics dismiss the asset as a volatile pump-and-dump scheme.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is currently trending as investors weigh potential federal trust bank regulatory breakthroughs against ongoing macro volatility and sector-specific downgrades. The community remains sharply divided, with bulls pointing to long-term institutional adoption and pending legislative clarity, while bears focus on declining trading volumes and technical price weakness.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

Kendu is actively trending as community members highlight its unique status as a permissionless brand that encourages participants to build real-world products and businesses. Supporters are heavily focused on the project's long-term conviction, steady development of diverse initiatives, and its expanding multi-chain ecosystem.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is currently trending due to intense market speculation surrounding its proprietary Perkinamine polymer technology and its integration into major silicon photonics foundries like Tower Semiconductor and GlobalFoundries. The community is actively debating the stock's potential as a critical AI infrastructure play versus concerns about its pre-revenue status and history of insider selling, with many investors closely watching for signs of commercial volume production to justify the company's valuation.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Organon & Co.

Organon & Co. is currently trending following an internal probe into sales practices that led to the resignation of its CEO, triggering significant volatility and investor concern regarding the company's future governance and financial outlook. While some market participants are wary of the audit findings, others are actively debating whether this sell-off presents a deep-value opportunity given the company's debt reduction efforts and core product portfolio.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is surging to all-time highs as investors pile into the stock ahead of its upcoming Nasdaq-100 index inclusion. The community is intensely debating whether this rapid, AI-driven rallywhich has seen the stock climb over 2,000% in a yearis a sustainable shift in market leadership or an overextended bubble nearing a potential reversal.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending as investors debate the impact of AI agent competition against the company's strong fundamentals and established enterprise role. While the community remains polarized by recent volatility and technical support levels, many are focused on the potential for strategic shifts or buybacks to challenge the prevailing short interest.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is currently trending as investors debate its execution and scaling capabilities within the high-performance computing and AI infrastructure sector. The community is actively discussing the company's competitive positioning against peers like Iris Energy and Applied Digital, with significant focus on its power capacity build-out, potential institutional interest, and upcoming site developments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy

Mustang Bio surges 180% after its brain cancer therapy, MB-101, earns FDA Orphan Drug status for two rare brain tumor types.

Mustang Bio generated increased retail chatter on Monday after the company said that the FDA had awarded Orphan Drug Designation to its experimental CAR-T drug MB-101 for the treatment of astrocytomas and glioblastoma (GBM), two types of fast-growing brain tumors.The treatment, which targets the IL13Ra2 protein, is currently being studied in a Phase 1 trial.&nbsp;In early results published in Nature Medicine, MB-101 was well-tolerated, with 50% of patients seeing stable disease or better.&nbsp;Among them, two had partial responses, and two others achieved complete responses lasting 7.5 months and more than five and a half years.Mustang is also looking at a combo approach, pairing MB-101 with MB-108, an HSV-1-based oncolytic virus, in a regimen it calls MB-109.&nbsp;Preclinical studies suggest that MB-108 may help modify the tumor microenvironment, essentially turning "cold" tumors into "hot" ones to improve efficiency of MB-101 CAR-T cells.MB-108 already has Orphan Drug status for malignant glioma, and Mustang says the combination could allow MB-101 to move more effectively through the tumor, activate in the right spots, and target cancer cells more precisely.Both MB-101 and MB-108 are still enrolling patients in Phase 1 studies, including one at City of Hope, the other at The University of Alabama at Birmingham.&nbsp;However, moving the MB-109 program forward will depend on whether the company can secure more funding or land a partnership deal.Orphan Drug status gives MB-101 access to several FDA benefits, including seven years of market exclusivity if approved, tax breaks on clinical trial costs, and waived fees, which are all part of a program designed to support treatments for rare conditions affecting fewer than 200,000 people in the U.S.On Stocktwits, retail sentiment for Mustang Bio was ‘extremely bullish’ amid a 105,200% surge in 24-hour message volume.One user on Stocktwits suggested that shares of $MBIO could climb to the $15–$20 range if the company secures a partnership, noting the stock “has life” and is poised to grow, especially for those who bought in below $1.20.<stembedurl>https://stocktwits.com/Invest2live/message/620129007</stembedurl>Another user speculated that a partnership or buyout by a larger pharmaceutical company could be in play, calling the day’s FDA designation “great news” for&nbsp;<a href="https://stocktwits.com/symbol/MBIO">Mustang Bio</a>.<stembedurl>https://stocktwits.com/BostonBigBoyisBack/message/620124257</stembedurl>The stock has declined 68% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Illustration depicting tumour infiltrating lymphocyte (TIL) therapy for cancer treatment. During TIL therapy, T-cells (blue) that recognise tumour cells (red) are obtained from a patient. | Image source: Getty Images

Mustang Bio Ignites Bullish Retail Buzz As FDA Grants Orphan Status To Brain Cancer Drug

The company is advancing a novel combination of its CAR-T drug MB-101 and oncolytic virus MB-108, with both treatments currently enrolling patients in Phase 1 trials. 

Equity

The biotech sector is already buzzing with retail investor interest as the new year begins. Here’s a look at the top three biotech stocks driving conversations on Stocktwits based on message volume jumps on the first trading day of 2025:Carmell Corp (CTCX): +58,100% Message VolumeRegenerative medicine biotech Carmell Corp surged into the spotlight after announcing an acquisition deal with PMGC Holdings’ Elevai Skincare subsidiary. The transaction includes $1.1 million in Carmell stock, $57,000 in cash, and contingent earnouts linked to Elevai’s product sales and revenue milestones.&nbsp;Carmell expects to acquire Elevai’s skincare and haircare portfolio, including a commercial team and inventory with $2.5 million in trailing revenue.&nbsp;Shares rocketed 148% on Thursday but saw some profit-taking early on Friday. Carmell’s stock lost roughly 80% last year.Mustang Bio (MBIO): +27,200% Message VolumeMustang Bio shares climbed 18% on Thursday and gained further in Friday’s pre-market, despite no apparent catalyst.&nbsp;In November, the company secured an extension from Nasdaq to meet compliance requirements and received FDA Orphan Drug Designation for MB-108, an oncolytic virus treatment for malignant glioma.&nbsp;While the stock fell nearly 85% in 2024, recent developments have sparked renewed optimism among investors.Revelation Biosciences (REVB): +9,150% Message VolumeRevelation Biosciences rose 42% on Thursday before sliding in Friday’s pre-market session without any catalyst.&nbsp;Retail buzz centers on its investigational therapy, Gemini, which received FDA clearance last month for a Phase 1b trial targeting chronic kidney disease patients.&nbsp;However, concerns around the company’s cash burn and financing moves have tempered investor enthusiasm. REVB shares dropped over 90% in 2024, leaving the stock a speculative favorite entering 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

Carmell, Mustang Bio, Revelation Biosciences Dominate Retail Biotech Talk As 2025 Kicks Off

From acquisition news and FDA designations to fresh optimism for struggling stocks, these biotechs piqued Stocktwits users the most on the first trading day of 2025.

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the translation of medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline includes CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors, and gene therapies for rare genetic disorders. The company was founded on March 13, 2015 and is headquartered in Waltham, MA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '24	-$0.14	-$17.50	-12400.00%	MISSED
Q1 '24	-$0.46	--	--	N/A

MBIO
Mustang Bio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q1 '24

Historical Earnings

Latest MBIO News

MBIOMustang Bio Inc